The appearance of side effects in patients treated with dupilumab for atopic dermatitis, already extensively described in the literature [194, 195], has made it possible to demonstrate the efficacy of upadacitinib, a JAK2 inhibitor, in a case of atopic dermatitis severe and AKC [196]. This evidence concerns the gene JAK2 and atopic eczema.